Eovist is a contrast dye used during MRI scans to help doctors see the liver more clearly. Its generic name is gadoxetate disodium, and it belongs to a class of imaging agents called gadolinium-based contrast agents. What makes Eovist different from standard MRI contrast is that liver cells actively absorb it, which lets radiologists spot tumors, lesions, and other abnormalities that might otherwise blend into the surrounding tissue.
How Eovist Works in the Liver
Most MRI contrast agents stay in the bloodstream. They flow through blood vessels, brighten them on the scan, and then get filtered out by the kidneys. Eovist does this too, but it has an additional trick: liver cells pull it inside through specialized transport proteins on their surface. Healthy liver cells take up the contrast and glow brightly on the scan. Abnormal tissue, like a tumor, typically lacks these transport proteins and stays dark by comparison.
This creates a sharp visual contrast between normal liver and problem areas. The effect peaks about 20 minutes after injection, during what’s called the hepatobiliary phase. Some radiologists wait up to 30 minutes to allow even the bile ducts and gallbladder to fill with contrast, giving a more complete picture of the entire biliary system. Once Eovist has done its job, the body clears it in roughly equal parts through the kidneys and the liver’s bile drainage system.
What Eovist Helps Diagnose
Eovist is particularly useful for identifying a benign liver growth called focal nodular hyperplasia (FNH). Because FNH contains functioning liver cells, it absorbs the contrast and appears bright on the delayed hepatobiliary images, while most other lesions stay dark. This distinction helps doctors tell FNH apart from other masses without needing a biopsy. In multicenter studies, Eovist produced higher lesion visibility during the hepatobiliary phase than other contrast agents for this purpose.
Beyond FNH, Eovist is used to evaluate a range of liver conditions: small metastases from cancers elsewhere in the body, hepatic adenomas, and suspicious nodules in patients with chronic liver disease. Its ability to highlight the difference between tissue that functions like normal liver and tissue that doesn’t makes it a go-to choice when standard imaging leaves questions unanswered.
How It Compares to Standard MRI Contrast
For some diagnoses, standard (extracellular) contrast agents actually perform better than Eovist. This is especially true for hepatocellular carcinoma, the most common primary liver cancer. Standard contrast is given at four times the gadolinium dose of Eovist (0.1 mmol/kg versus 0.025 mmol/kg), and comparative studies have found that higher dose produces clearer detection of key cancer features like “washout,” where a tumor loses its brightness faster than surrounding tissue.
In head-to-head research, standard-dose extracellular contrast was at least equivalent, and in some cases superior, to Eovist for diagnosing hepatocellular carcinoma using the LI-RADS scoring system that radiologists rely on. The differences were most pronounced for small tumors measuring 1 to 2 centimeters. So the choice of contrast agent depends on the clinical question: Eovist excels at characterizing certain benign lesions and detecting small metastases, while standard contrast can be the better option for primary liver cancer screening.
What to Expect During the Scan
Eovist is given as a single injection into a vein, typically in your arm, at a rate of about 2 milliliters per second. The dose is weight-based (0.1 mL per kilogram of body weight), so a person weighing around 70 kg would receive roughly 7 mL, a small volume compared to CT contrast dyes. No fasting or special dietary preparation is required beforehand.
The MRI itself takes longer than a standard contrast-enhanced scan. After the injection, the radiologist captures images in the first couple of minutes as the dye flows through blood vessels (the dynamic phase), then waits approximately 20 minutes before capturing the hepatobiliary phase images. This waiting period is built into the scan, so expect the total appointment to run longer than a typical MRI. You’ll remain in the scanner during this time, though some facilities use the gap to acquire other imaging sequences.
Eovist is approved for adults only. Its safety and effectiveness have not been established in children.
Side Effects and Safety
The most commonly reported side effects are mild: nausea, headache, warmth or flushing at the injection site, and dizziness. Serious allergic reactions are rare but possible, as with any gadolinium-based contrast agent.
One concern that comes up with all gadolinium contrast agents is nephrogenic systemic fibrosis (NSF), a serious condition involving thickening of the skin and connective tissue that occurs almost exclusively in people with severe kidney disease. Eovist is classified in the lowest-risk category for NSF. Research from the VA health system found that gadolinium levels remaining in the body after Eovist are lower than after some other agents, and European regulators have classified gadoxetate disodium as a contrast agent that can be used without additional patient consent requirements, reflecting its favorable safety profile. That said, kidney function is still checked before administration, because even lower-risk agents warrant caution in people with significantly impaired kidneys.